Brought to you by 
Series C brings in $69mm for Pearl Therapeutics
21 Oct 2010
Executive Summary
Vatera Healthcare Partners has led Pearl Therapeutics Inc.'s (combination therapies for chronic respiratory diseases) $69mm Series C venture round. (Vetera will contribute one board member and appoint a board observer.) Current shareholders Clarus Ventures, New Leaf Venture Partners, and 5AM Ventures also participated. The funds will be used to complete the Phase IIb study for Pearl's lead drug candidate, PT003 (glycopyrrolate/formoterol), a bronchodilator for COPD; Phase III should start before the end of 2012. The company has brought in $102.5mm since 2007.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in $69mm for Pearl Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice